-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
whichholidays.
whichholidays.
Studies have found that in Africa, mutations are related to delayed clearance of parasites in children with malaria treated with common penicillin combination therapy ( ACTs ) .
The new research data provides the first clinical evidence that the drug-resistant mutation of Plasmodium falciparum may be gaining a foothold in Africa.
The study also found that these mutations are more common than previous research reports, indicating that mutations may spread and cause people to worry about the further geographical distribution of drug resistance.
It is estimated that there are 229 million cases of malaria worldwide , and 409,000 people died of malaria in 2019 , of which 274,000 ( 67% ) were among children under 5 years of age.
Mutations can appear spontaneously, and previous studies have pointed out isolated cases of resistance.
Co-author, Dr.
2000 early years of the introduction of penicillin-based combination therapies ( ACTs ) are currently the most effective and widely used for the treatment of malaria caused by Plasmodium falciparum method.
If the parasite is still present after the third day of treatment ( called delayed parasite clearance ), it is suspected of resistance to the penicillin component called delayed parasite clearance called delayed parasite clearance ACT .
In 2008 , Cambodia first discovered some penicillin resistance.
In 2006 , Rwanda introduced methyl ether - luciferin (an ACT and the most widely used antimalarial drug) as a first-line treatment for malaria.
A study of this type was conducted in Rwanda, Rwanda, and Masaka between 1-14 years of age in 2013-2015 .
In 2018 , another efficacy study was conducted and the results were published in this article.
The study was conducted in three locations in Rwanda (Masaka, Rukala and Bugarama).
San Francisco University of California Philip · Professor Rosenthal ( Philip Rosenthal ), wrote in a commentary in the connection: " Recent data show that we are on the edge of clinically meaningful penicillin resistance in Africa, As it appeared in Southeast Asia more than ten years ago.
Original link: (The link will be online when the ban is lifted)
Leave a message here
